Novo's CSO Has A Lifetime Product Plan For Diabetes Patients

Novo Nordisk's executive vice president and chief scientific officer, Dr. Mads Krogsgaard Thomsen, talks to Scrip about the Danish firm's biggest challenges as a leader in the development of diabetes therapies – including the positioning of its numerous marketed type 2 diabetes therapies and how the company can stay innovative in a saturated disease space.

Mads Thomsen

Novo Nordisk AS's biggest dilemma, according to chief scientific officer Mads Krogsgaard Thomsen, is how the company can position all of its diabetes products in the market to avoid cannibalization of the drugs and to ensure patients get the benefit of the best-suited treatment for their diabetes.

"We have a multitude of products for the same disease," Krogsgaard Thomsen told Scrip in a recent exclusive interview following...

More from Business

More from Scrip

KalVista’s Delayed FDA Approval In HAE Comes Through

 
• By 

KalVista’s Ekterly obtains US approval as the first oral, on-demand therapy for hereditary angioedema. It will compete with established injectables.

Cogent Peaks With Bezaclastinib SUMMIT Results

 

The biotech announced positive topline results from the Phase II SUMMIT study in non-advanced systemic mastocytosis, with data for advanced SM and GIST expected later this year.

France’s AB Science Plots Pivotal Masitinib Trial In Prostate Cancer

 
• By 

Still holding out hope after multiple rejections for the tyrosine kinase inhibitor.